MiNK Therapeutics (INKT) Stock: Buy, Sell, or Hold?
INKT - MiNK Therapeutics, Inc. Common Stock
$10.71
0.65 (6.46%)
▲
5d:
+13.82%
30d:
-12.93%
90d:
+1.13%
BUY
HIGH Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 13, 2026
19d
Get Alerted When INKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INKT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: INKT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: INKT is currently trading at $10.71, which is considered slightly low relative to its 30-day fair value range of $10.36 to $12.33.
Technical Outlook: Technically, INKT is in a downtrend. Immediate support is located at $9.19, while resistance sits at $11.68. The stock is showing strong short-term momentum, up 6.5% recently.
Market Sentiment: INKT scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $42.50 (+296.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INKT is in a downtrend. Immediate support is located at $9.19, while resistance sits at $11.68. The stock is showing strong short-term momentum, up 6.5% recently.
Market Sentiment: INKT scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $42.50 (+296.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$10.36 -
$12.33
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (78/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.5%)
- BULLISH: Trading 296.8% below Wall St target ($42.50)
- BULLISH: Bottoming setup score 78/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$10.36 -
$12.33
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$9.19
Resistance Level
$11.68
Current Trend
Downtrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.89
Wall Street Target
$42.50
(+296.8%)
Share & Embed Analysis
Last updated: October 23, 2026 10:54 PM ET
Data refreshes hourly during market hours. Next update: 11:54 PM
Data refreshes hourly during market hours. Next update: 11:54 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$197 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$109 | 64 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
19 analysts |
$686 | 48 HOLD |
|
PVLA
Palvella Therapeutics, I… |
STRONG BUY
15 analysts |
$231 | 60 HOLD |
